The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The RAD51-FFPE Test; Calibration of a Functional Homologous Recombination Deficiency Test on Diagnostic Endometrial and Ovarian Tumor Blocks
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 12, Pages 2994
Publisher
MDPI AG
Online
2021-06-15
DOI
10.3390/cancers13122994
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Modification of Homologous Recombination Deficiency Score Threshold and Association with Long-Term Survival in Epithelial Ovarian Cancer
- (2021) Jeffrey A. How et al. Cancers
- Homologous recombination deficiency status-based classification of high-grade serous ovarian carcinoma
- (2020) Hisamitsu Takaya et al. Scientific Reports
- ESMO recommendations on predictive biomarker testing for homologous recombination deficiency and PARP inhibitor benefit in ovarian cancer
- (2020) R.E. Miller et al. ANNALS OF ONCOLOGY
- The RECAP Test Rapidly and Reliably Identifies Homologous Recombination-Deficient Ovarian Carcinomas
- (2020) Lise M. van Wijk et al. Cancers
- Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
- (2020) H.P. Eikesdal et al. ANNALS OF ONCOLOGY
- Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2019) Antonio González-Martín et al. NEW ENGLAND JOURNAL OF MEDICINE
- Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer
- (2019) Robert L. Coleman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer
- (2019) Isabelle Ray-Coquard et al. NEW ENGLAND JOURNAL OF MEDICINE
- RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
- (2018) C Cruz et al. ANNALS OF ONCOLOGY
- A functional homologous recombination assay predicts primary chemotherapy response and long-term survival in ovarian cancer patients
- (2018) Manuela Tumiati et al. CLINICAL CANCER RESEARCH
- Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
- (2018) Darren R. Hodgson et al. BRITISH JOURNAL OF CANCER
- Frequent Homologous Recombination Deficiency in High-grade Endometrial Carcinomas
- (2018) Marthe M. de Jonge et al. CLINICAL CANCER RESEARCH
- A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutation
- (2018) Marta Castroviejo‐Bermejo et al. EMBO Molecular Medicine
- Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer
- (2018) Kathleen Moore et al. NEW ENGLAND JOURNAL OF MEDICINE
- Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer
- (2017) Adriaan Vanderstichele et al. EUROPEAN JOURNAL OF CANCER
- Reversion of BRCA1/2 Germline Mutations Detected in Circulating Tumor DNA From Patients With High-Grade Serous Ovarian Cancer
- (2017) Elizabeth L. Christie et al. JOURNAL OF CLINICAL ONCOLOGY
- Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
- (2017) Robert L Coleman et al. LANCET
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures
- (2017) Helen Davies et al. NATURE MEDICINE
- Trabectedin as a chemotherapy option for patients with BRCA deficiency
- (2016) Bradley J. Monk et al. CANCER TREATMENT REVIEWS
- Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
- (2016) Mansoor R. Mirza et al. NEW ENGLAND JOURNAL OF MEDICINE
- Homologous Recombination Deficiency: Exploiting the Fundamental Vulnerability of Ovarian Cancer
- (2015) P. A. Konstantinopoulos et al. Cancer Discovery
- Assessing the function of homologous recombination DNA repair in malignant pleural effusion (MPE) samples
- (2014) M J Patterson et al. BRITISH JOURNAL OF CANCER
- Functional Ex Vivo Assay to Select Homologous Recombination-Deficient Breast Tumors for PARP Inhibitor Treatment
- (2014) K. A. T. Naipal et al. CLINICAL CANCER RESEARCH
- An ex vivo assay of XRT-induced Rad51 foci formation predicts response to PARP-inhibition in ovarian cancer
- (2014) Monjri M. Shah et al. GYNECOLOGIC ONCOLOGY
- Clinical Evaluation of a Multiple-Gene Sequencing Panel for Hereditary Cancer Risk Assessment
- (2014) Allison W. Kurian et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated analysis of germline and somatic variants in ovarian cancer
- (2014) Krishna L. Kanchi et al. Nature Communications
- Tumor Mutation Burden Forecasts Outcome in Ovarian Cancer with BRCA1 or BRCA2 Mutations
- (2013) Nicolai Juul Birkbak et al. PLoS One
- Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer
- (2012) V Abkevich et al. BRITISH JOURNAL OF CANCER
- Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation
- (2012) T. Popova et al. CANCER RESEARCH
- Clinicopathological Features of Homologous Recombination-Deficient Epithelial Ovarian Cancers: Sensitivity to PARP Inhibitors, Platinum, and Survival
- (2012) A. Mukhopadhyay et al. CANCER RESEARCH
- Secondary Somatic Mutations Restoring BRCA1/2 Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
- (2011) Barbara Norquist et al. JOURNAL OF CLINICAL ONCOLOGY
- Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing
- (2011) T. Walsh et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- 53BP1 Inhibits Homologous Recombination in Brca1-Deficient Cells by Blocking Resection of DNA Breaks
- (2010) Samuel F. Bunting et al. CELL
- A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
- (2010) M. Graeser et al. CLINICAL CANCER RESEARCH
- Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
- (2010) A. Mukhopadhyay et al. CLINICAL CANCER RESEARCH
- 53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers
- (2010) Peter Bouwman et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Utility of DNA Repair Protein Foci for the Detection of Putative BRCA1 Pathway Defects in Breast Cancer Biopsies
- (2009) H. Willers et al. MOLECULAR CANCER RESEARCH
- Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
- (2008) Wataru Sakai et al. NATURE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More